Biocept is offering 6.25 million shares of its common stock and warrants to purchase up to 6.25 million shares of the common stock at a combined price $1.20 per share and warrant.
Opko will use the proceeds to fund R&D to further develop its diagnostics and pharmacy portfolio, and for working capital including debt repayment.
The firm plans to use the funding to drive sales of its preimplantation genetic screening tests and to invest in data science.
The transaction included the conversion of a $2 million note, eliminating the company's debt, as well as the sale of $1 million in preferred shares.
The funds will help commercialize Ador's NATlab reader, a point-of-care MDX platform for sample-to-answer identification of specific infectious diseases.
The firm said it raised €55.5 million to fund the expansion of its Idylla test platform, its sales and marketing activities, and other general corporate purposes.
The Boston-based startup will use the funds to expedite prototype development of its sample preparation technology and computational approach.
The financing will go toward continued development of its MultiPath technology to rapidly identify hospital infections and determine their antibiotic susceptibility.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The firm noted that it has already borrowed $350 million under the revolving credit facility. The funds may be used for general corporate and other purposes.